⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 1, 2017

Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.

Victor James Drew Lassina Barro Jerard Seghatchian Thierry Burnouf

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to enhance blood safety by inactivating viral DNA and RNA in red blood cells and whole blood.
Evaluated S-303 system in phase III clinical trial for whole blood.
Investigated methodologies for both whole blood and component preparation.
Focused on technologies for viral reduction in blood products.
Demonstrated effectiveness of S-303 system in reducing viral agents in blood products.
Showed potential applicability of methodologies to whole blood and red blood cell components.
Results support further development of blood safety technologies in resource-limited settings.

Implication

Assesses viral DNA/RNA inactivation in blood, suggesting new technologies for developing countries.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Drew et al. (2017) studied this question.

synapsesocial.com/papers/6a1feeefc1b320180d0da8af https://doi.org/10.2450/2017.0344-16

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pathogen reduced red blood cells as an alternative to irradiated and washed components with potential for up to 42 days storage.2024 · 4 citations
2Advances in pathogen reduction technologies: enhancing safety and functionality of blood productsOriginal Research · 2026 · 1 citations
3Pathogen Reduction of Transfused Blood Components—The End of the Beginning Rather than the Beginning of the EndReview · 2026 · 1 citations
4Pathogen-Reduced Low-Titer Group O Whole Blood for Managing Massive Blood Loss in Prehospital and Early Hospital Settings: An In Vitro Study2025
5Development of a sensitive PCR inhibition method to demonstrate HBV nucleic acid inactivationDiagnostic Study · 2004 · 11 citations